Health
FDA advisory panel evaluates Grail's multi-cancer blood test for regulatory approval
Advisers meet to review clinical data for the Galleri test, NPR reports.
The short version
- An FDA advisory committee is convening to vote on whether to recommend approval for Grail's Galleri multi-cancer blood test.[NPR]
- Grail reports the $949 test can detect up to 50 types of cancer, but trial interpretation remains debated after it missed its primary endpoints.[NPR]
- The FDA frequently follows panel recommendations, and an eventual approval could unlock insurance reimbursement for patients.[NPR]
Key facts
- An FDA advisory committee meets to vote on whether to recommend approval of Grail's Galleri multi-cancer blood test.[NPR]
- Grail states that the $949 screening test can identify up to 50 forms of cancer.[NPR]
- The panel is examining studies of more than 140,000 U.K. patients and over 35,000 North American participants aged 50 and older.[NPR]
- The clinical trials did not achieve their primary endpoints of cutting overall mortality or combined Stage III and IV cancers.[NPR]
- FDA approval would mark the first for a multi-cancer blood test and could enable insurance reimbursement.[NPR]
What remains uncertain
- Whether the FDA will adopt the advisory panel's recommendation remains uncertain, as the agency is not mandated to follow advisory votes.[NPR]
- The clinical significance of trial data remains disputed because the test missed primary mortality endpoints despite showing later drops in Stage IV diagnoses alone.[NPR]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.